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Objective: Currently our standard of practice is that patients undergoing carotid artery stenting (CAS) may be safely
discharged on the first day post-procedure. However, many patients are completely independent on the evening of
procedure. Therefore we sought to establish the safety and feasibility of same-day discharge by assessing frequency and
time of complications in the first 30 days after CAS.
Method: Case records for 208 consecutive patients who had undergone CAS from October 1999 to October 2002 were
retrospectively reviewed. Excluded were four cases in which combined CAS and carotid endarterectomy was performed
to treat synchronous stenosis. Of the remaining 204 cases, involving 201 patients (three patients underwent staged
bilateral CAS), 173 (84.8%) were symptomatic and 31 (15.2%) were asymptomatic.
Result: Thirty-eight major events or death (inclusive of all neurologic events and any complications that required
treatment) were recorded in the first 30 days after CAS, for an event rate of 18.6% per case. These were 7 (3.4%) major
access site complications; 18 (8.8%) neurologic events, of which 10 (4.9%) were transient ischemic events and 8 (3.9%)
were strokes (including minor, major, and fatal stroke); 8 (3.9%) cardiovascular complications; and five (2.5%) other
events. Twenty (52.6%) events occurred in the first 6 hours after CAS, 2 (5.3%) between 6 and 12 hours, 3 (7.9%) between
12 and 24 hours, and 13 (34.2%) 24 hours to 30 days post procedure. Four (2.0%) deaths were recorded in this period,
1 secondary to stroke, 1 from a perforated myocardium from a temporary pacing wire, and 2 from unrelated causes. The
30-days stroke and death rate was 5.4% (11 of 204 patients).
Conclusion: Time of complications suggests that outpatient performance of CAS is feasible and safe in selected patients.
(J Vasc Surg 2003;38:236-43.)
Carotid artery stenting (CAS) is becoming increasingly
common for endovascular treatment of carotid artery ste-
nosis. Accumulating data suggest that CAS has promising
efficacy in preventing stroke, with an acceptable rate of
procedure-related complications when compared with ca-
rotid endarterectomy.1-3 Two large trials comparing endo-
vascular treatment and surgery, the Carotid Revasculariza-
tion Endarterectomy versus Stent Trial (CREST)4 and the
International Carotid Stenting Study (ICSS)5 are currently
under way.
Initially, care of patients after CAS has consisted of
close observation for 24 to 48 hours in high-dependent
(stepdown) or intensive care units before transfer to the
general ward and subsequent discharge. This system has
been truncated considerably over the last few years, to
overnight observation in a general ward, as in our unit.
However, advances in endovascular technique, increasing
proficiency with the procedure, and ongoing desire for cost
containment have led to the suggestion that CAS can be
performed as an outpatient procedure.6 The dangers of
performing outpatient CAS are delayed complications and
patient inability to not only recognize that there is a prob-
lem but also to obtain prompt medical attention. Further-
more, it is not clear what the optimal observation period
should be, because information on the time of complica-
tions after CAS is limited.
This issue is critical to patient care and safety. We
therefore evaluated the severity, frequency, and time of
complications in the first 30 days after CAS in our unit.
MATERIALS AND METHODS
Patients
We retrospectively reviewed the medical and nursing
records for 208 consecutive CAS performed in Central
Sheffield teaching hospitals over the 3 years from October
1999 to October 2002. Patients were selected for CAS
from the weekly multidisciplinary stroke team meeting,
consisting of interventional vascular radiologists, neurolo-
gists, and vascular surgeons, and identified in a local registry
maintained by the department of neurology. The primary
criterion for CAS was either symptomatic extracranial ICA
stenosis (70%) involving the carotid bulb or asymptom-
atic stenosis (70%) before major surgery, eg, coronary
artery bypass grafting or aortic aneurysm repair. The degree
of stenosis was measured with duplex ultrasound (US)
scanning and arch aortography, according to the North
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American Asymptomatic Carotid Endarterectomy Trial
(NASCET) method.7 Patients were selected for carotid
endarterectomy if arch aortographs showed tortuous arch
vessels, which could prevent successful stent delivery, or a
low tonsillar loop close to the stenosis, which could pre-
clude use of cerebral protective devices. Patients with “high
risk neck,” eg, because of previous radiation therapy, radi-
cal surgery, or high internal carotid artery stenosis, were
selected for CAS. Most patients who were candidates for
either surgical or endovascular treatment were recruited
into ongoing trials. For patients without symptoms before
coronary artery bypass surgery, a decision regarding neces-
sity for treatment was made in the multidisciplinary meet-
ing. An attending vascular radiologist (T.J.C., P.A.G.) or
fellow under close direct supervision performed all CAS
procedures.
Procedures
Pre-CAS protocol. All patients underwent duplex US
scanning and arch aortography to assess the anatomy and
degree of stenosis 1 to 2 months before CAS. Duplex US
scanning was done by experienced medical technicians who
performed such examinations regularly. Digital arch aor-
tography was performed via a femoral approach, with a 5F
pigtail catheter positioned in the ascending aorta. Images in
five projections were obtained: one posteroanterior and
two oblique (45% and 75%) on each side.
All patients received full antiplatelet therapy, consisting
of clopidogrel 75 mg daily for at least 3 days or a loading
dose of 300 mg 2 hours before the procedure. National
Institutes of Health (NIH) Stroke Scale assessment was
performed by a neurologist before and within 24 hours
after CAS.
CAS technique. CAS was performed with the patient
under local anesthesia without sedation. Blood pressure,
pulse, and oxygen saturation were continuously monitored
throughout the procedure, and neurologic assessment was
performed by experienced nursing staff. Access to the com-
mon femoral artery was achieved with the Seldinger tech-
nique. A sheath was then inserted into the artery. Heparin,
5000 U, was given before selective catheterization of the
common carotid artery with a suitable catheter–guide wire
combination. The guide wire was then exchanged for a stiff
guide wire, which was used for cannulation of the external
carotid artery. The femoral access sheath was removed, and
an 80 cm 7F Super Arrow-Flex sheath (Arrow Interna-
tional) was placed, over the guide wire, 2 cm inferior to the
carotid bifurcation. The guide wire was then removed, and
selective angiography via the sheath side port was carried
out. The diameter of the internal and common carotid
arteries was measured, and a stent sized to the common
carotid artery diameter was selected. A 0.14-inch or 0.18-
inch floppy tip wire was advanced through the Arrow-Flex
sheath, navigated across the stenosis, and positioned in the
distal arterial segment, under roadmap guidance. After
administration of 1.2 mg of atropine, a 3 mm coronary
angioplasty balloon (Gazelle; Boston Scientific, Boston,
Mass) was used to dilate the stenosis so that the stent
delivery system could cross the lesion smoothly. After dila-
tion, a stent was selected (dependent on operator prefer-
ence, lesion characteristics, and commercial availability)
and placed across the stenosis. Post-dilation, to the diame-
ter of the internal carotid artery, was performed if there was
residual stenosis. Completion angiography was then per-
formed, and a closure device was used to achieve hemostasis
in most cases.
Post-procedure protocol. The patient was trans-
ferred to a vascular or neurology ward for observation, ie,
pulse and blood pressure measurement, puncture site in-
spection, and basic neurologic assessment, every 1 to 2
hours for 24 hours or until discharge. A physician further
evaluated any episode of neurologic change or complica-
tion detected by nursing staff. Mobilization was dependent
on whether a hemostatic device had been used: when such
a device was used, full mobilization was allowed 3 hours
after the procedure; if no device was used or deployment
failed, the sequence was 4 hours of bed rest, 1 hour of
sitting up, then full mobilization. Approximately 24 hours
after CAS a neurologist carried out a formal NIH Stroke
Scale assessment. Patients were discharged to home if no
complications occurred within the first 24 hours of obser-
vation. After CAS, all patients received clopidogrel (75 mg
daily) for 28 days, followed by long-term aspirin (75 mg
daily) therapy.
Patient follow-up. All patients were seen in the neu-
rology or vascular outpatient clinic at 30 days, 6months, 12
months, and yearly thereafter. Patients were instructed to
inform the coordinator (research nurse) or general practi-
tioner if any symptoms possibly related to an ischemic event
occurred after hospital discharge, in which case the patient
was seen urgently in the outpatient clinic. If a neurologic
event had possibly occurred, a neurologist assessed the
patient, and computed tomography or magnetic resonance
imaging, and duplex US scanning were performed. When
any patient died, the cause of death was identified from the
death certificate or postmortem findings.
Data acquisition
Medical and nursing records were reviewed to deter-
mine nature and time of complications in the first 30 days
after CAS; any active treatment initiated by the medical or
nursing staff while the patient was hospitalized or after
discharge; length of stay in hospital after CAS and reason
why discharge was later than 24 hours post-procedure; and
any readmission to the hospital. Active treatment was de-
fined as administration of any action, physical or pharma-
cologic, aside from regular treatment for that patient.
Complications were divided into four categories: access
site–related, neurologic, cardiovascular, and other compli-
cation.
Access site complications were classified as minor or
major. Minor complications were defined as those that
could be dealt with during the procedure, those requiring
conservative treatment, or those that did not result in delay
of discharge. Major complications included those requiring
surgery, transfusion, or intervention or that resulted in
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delay of discharge. Neurologic events were defined as tran-
sient ischemic event, ie, a new focal retinal or hemispheric
event from which the patient made a complete recovery
within 24 hours; minor stroke, ie, a new neurologic event
that either resolved completely within 7 days or increased
NIH Stroke Scale score by 3 or less; major stroke, ie, a new
neurologic deficit that persisted for more than 7 days and
increased the NIH score by 4 or more; and fatal stroke, ie,
death attributable to an ischemic event or intracerebral
hemorrhagic stroke.
Cardiovascular complications included cardiac arrhyth-
mias, hemodynamic instability, and myocardial ischemia. A
subanalysis of changes in hemodynamic parameters (systol-
ic and diastolic pressure) in patients with post-procedure
symptomatic hypotensive events, compared with patients
with no symptoms, was performed with the unpaired t test.
RESULTS
From October 1, 1999, to October 1, 2002, 208 CAS
procedures were performed in 205 patients (3 patients
underwent staged bilateral CAS). Four patients underwent
combined common carotid artery stenting and carotid
endarterectomy, and were excluded from the study. Of the
remaining 201 patients, 204 CAS procedures were per-
formed to treat 173 (84.8%) symptomatic and 31 (15.2%)
asymptomatic stenoses. Cerebral protective devices were
used in 135 (66.2%) procedures. Patient mean age (SD)
was 68 plusmn; 8.3 years; 68% of patients were men, and
32% were women. The patients had the expected mix of
comorbid conditions: hypertension, 63%; diabetes, 18%;
ischemic heart disease, 47%; and hyperlipidemia, 41%.
Duration of hospitalization
Of 204 patients, 177 (86.8%) were discharged the day
after the procedure and 27 (13.2%) stayed in hospital for 2
or more nights. Reasons for delayed discharge included
symptomatic hypotension (n  7), neurologic event (n 
4), access site complication (n 4), social circumstances (n
 3), elective coronary bypass grafting (n  2), contrast
material–induced renal impairment (n  2), urinary reten-
tion (n  1), chest infection (n  1), repeat warfarin
therapy (n 1), elevated blood glucose concentration (n
1), and ventricular tachycardia (n  1). Six patients (social
circumstances, n 3; coronary bypass grafting after CAS, n
 2; and repeat warfarin therapy, n  1) were deemed not
suitable for early discharge; and if this group were excluded
from analysis, 89.4% (177 of 198) patients could be dis-
charged after overnight stay.
Frequency and time of complications
In the first 30 days, 38 patients experienced 38 compli-
cations from the 204 procedures, for an overall complica-
tion rate of 18.6% (Table I). Of these 38 complications, 20
(52.6%) occurred at or within 6 hours of the procedure, 2
(5.3%) occurred between 6 and 12 hours, 3 (7.9%) oc-
curred between 12 and 24 hours, and 13 (34.2%) occurred
after 24 hours (Fig 1). Four deaths (2.0%) occurred in the
first 30 days post-procedure; one was directly related to the
procedure (perforated myocardium from temporary pacing
wire in a patient with a history of sick sinus syndrome), one
was secondary to major stroke 10 days post-CAS, and two
causes unrelated to the procedure.
Complications related to access site. One hundred
eighty-one Angio-Seal devices (St Jude Medical,
Minnetonka, Minn) and 20 Closer devices (Perclose, Red-
wood City, Calif) were deployed. In 3 patients manual
compression was applied for hemostatic control. Nine mi-
nor complications (4.4%) and seven major complications
(3.4%) were recorded, for a total complication rate of 7.8%
per access site.
In the Angio-Seal group, eight local complications
occurred (five minor, three major). The five minor compli-
cations were slight ooze immediately after deployment,
which was controlled easily with a short period of manual
compression. The three major complications were as fol-
lows. One patient had persistent ooze for 24 hours post-
procedure, which required prolonged compression, thus
delaying hospital discharge by 1 day. In another patient,
who was receiving heparin infusion post-CAS as part of a
trial, bleeding recurred 5 hours after deployment of the
Angio-Seal device and required 30minutes of compression.
Activated partial thromboplastin time was more than 180
seconds (normal range, 28-36 seconds). The third patient,
who had no history of peripheral vascular disease, returned
7 days after CAS with sudden onset of short distance limb
claudication. A diagnostic angiogram showed occlusion of
the common femoral artery. Surgical exploration 3 months
later revealed dissection of the common femoral artery,
most likely secondary to Angio-Seal misplacement.
The 20 Closer devices were deployed with one imme-
diate technical failure, which required conversion to man-
ual compression. This patient had a small hematoma post-
procedure, but no further treatment was required and
hospital discharge was not delayed. In 1 patient an infected
false aneurysm developed 2 weeks after the procedure,
Table I. Frequency of complications within 30 days after
carotid artery stenting
Complications
Number
of events
Percent
of cases
Access site
Minor 9 4.4
Major 7 3.4
Neurologic
Transient ischemia 10 4.9
Nondisabling stroke 2 1.0
Disabling stroke, death 6 2.9
Cardiovascular
Symptomatic hypotension 7 3.4
Perforated myocardium
from pacing wire
1 0.5
Other events
Contrast medium–induced
nephropathy
2 1.0
Urinary retention 2 1.0
Chest infection 1 0.5
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which required excision of the aneurysm and bypass sur-
gery. A short period of compression was needed in 1 patient
with minor ooze immediately post-procedure.
No hemostatic devices were used in 3 patients, and
major access site complications developed in all of them.
One patient had a large false aneurysm within 24 hours
after the procedure, which required thrombin injection and
prolonged stay of 8 nights. The procedure was technically
difficult, and a 9F sheath was used rather than the usual 7F
sheath, precluding use of a closure device. One patient
returned 3 days after the procedure with extensive groin
hematoma, and required 3 units of blood. Duplex US
scanning did not demonstrate any false aneurysm. The final
patient underwent external iliac stenting at the same time as
CAS. Inasmuch as the distal end of the iliac stent was very
close to the access site, the radiologist believed that use of a
closure device was inappropriate. After the procedure a
large hematoma developed, which required prolonged
compression and delayed discharge by 5 days.
Neurologic complications. Eighteen (8.8%) neuro-
logic events were recorded in the first 30 days after CAS
(Table II), including 10 (4.9%) transient ischemic events, 1
fatal stroke, 5 major strokes, and 2 minor strokes, for an all
stroke and fatal stroke rate of 3.9%. Eight (44.4%) events
occurred during or within 6 hours after the procedure.
Cardiovascular complications. Seven patients had
delayed hospital discharges secondary to symptomatic (diz-
zy, light-headed) hypotension that required supportive
Fig 1. Complications versus time.
Table II. Neurologic events
Sex
Age
(y) Indication Neurologic event Time
F 67 Transient ischemia Transient ischemia Immediate
F 52 Contralateral occlusion* Major stroke Immediate
M 63 Transient ischemia Transient ischemia Immediate
F 66 Minor stroke Minor stroke Immediate
F 77 Amaurosis fugax Transient ischemia Immediate
F 67 Amaurosis fugax Transient ischemia Immediate
F 77 Transient ischemia Transient ischemia Immediate
F 79 Amaurosis fugax Major stroke Immediate
F 65 Contralateral occlusion* Major stroke 2 d
M 70 Pre-CABG Major stroke 2 d
M 79 Transient ischemia Transient ischemia 3 d
M 55 Transient ischemia Transient ischemia 10 d
M 71 Transient ischemia Major stroke, death 10 d
F 74 Major stroke Minor stroke 11 d
M 66 Major stroke Transient ischemia 12 d
M 51 Transient ischemia Transient ischemia 14 d
M 56 Transient ischemia Transient ischemia 14 d
M 74 Pre-CABG Major stroke 19 d
CABG, Coronary artery bypass graft.
*Patients with an occluded carotid artery and70% stenosis on the contralateral side but symptoms remained on the occluded side. Carotid artery stenting was
performed on the asymptomatic side, and these patients were included in the asymptomatic group.
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measures. Of the seven events, six occurred within 4 hours
and 1 at 24 hours post-procedure. Two patients required
pharmacologic support, either phenylephrine or atropine
sulphate. The remainder of complications resolved with
bed rest. One patient with a history of unstable angina had
an episode of ventricular tachycardia after administration of
1.2 mg of atropine sulphate before dilation of the stenosis
for stent deployment. After a short period of cardiopulmo-
nary resuscitation, the patient recovered completely and
was discharged on day 6 after the procedure. No other
acute cardiac arrhythmias or coronary ischemic events were
recorded.
Subanalysis of hemodynamic changes. In the 7 pa-
tients with symptomatic hypotensive events post-proce-
dure, mean difference in systolic pressure before and imme-
diately after stenting was 42.9 mm Hg (95% confidence
interval [CI], 18.3-67.5 mm Hg; P  .05) and mean
difference in diastolic pressure was 22.0 mm Hg (95% CI,
13.0-31.0 mmHg; P .05) (Fig 2). In comparison, in the
197 patients with no symptomatic hypotensive events,
mean difference in systolic pressure before and after stent-
ing was 13.3 mmHg (95% CI, 8.0-18.6 mmHg; P .05)
and mean difference in diastolic pressure was 3.3 mm Hg
(95% CI, 0.3-6.3 mm Hg; P  .05). Mean difference in
systolic and diastolic pressure reduction in the symptomatic
group compared with the asymptomatic group was 29.6
mm Hg (95% CI, 7.3-51.9 mm Hg; P  .05) versus 18.7
mmHg (95% CI, 6.1-31.3 mmHg; P .05), respectively.
Other complications. Two patients required urinary
catheterization because of acute urinary retention; one had
benign prostatic hypertrophy. Another 2 patients had slight
deterioration in renal function (creatinine concentration,
206-292 mmol/L and 153-185 mmol/L, respectively),
which improved with intravenous fluid replacement and
discontinuation of diuretic agents and acetyl cholinesterase
inhibitor. One patient had a chest infection on the second
day after admission, which was treated with intravenous
antibiotics and physiotherapy.
Comparison of stents and cerebral protection devices
Wallstents (Boston Scientific) were used in 168 patients
(82.4%), and various other stents were used in the remain-
der of patients. The samples sizes were too small for mean-
ingful statistical analysis of complications or outcome be-
tween stents.
Cerebral protection devices were used in 135 (66.2%)
patients. Of these, 107 (79.3%) were the NeuroShield
device (MedNova Ltd, Galway, Ireland), and the remain-
der were various other devices. The 30-day neurologic
event rate in the protected and unprotected groups, respec-
tively, were 6.7% (9 of 135) and 13.0% (9 of 69) (P 
.200).
DISCUSSION
Although carotid artery stenting is a relatively new
procedure, it is rapidly becoming established as a safe and
effective alternative to carotid endarterectomy for treat-
ment of carotid artery stenosis.1-3 As with any new proce-
dure, safety is of paramount importance, and this is especially
true in CAS, in which it is compared with a well-established,
safe, and effective technique, carotid endarterectomy.7,8
When CAS was first used, patients were routinely monitored
in the intensive care unit for 24 to 48 hours after the proce-
dure. This, however, has not proved necessary in most cases,
and our current standard of care involves overnight observa-
tion in a surgical or neurology ward. Although this practice
appears safe, we observed that most patients were alert, inde-
pendent, mobile, and did not seem to require hospitalization
by the evening of the day of the procedure. This begs the
questions of whether overnight stay is necessary for all patients
undergoing CAS and what can be gained by same-day dis-
charge.
However, before we alter our practice, it is essential to
review the method of changing a patient care algorithm. A
cohort of patients should be retrospectively evaluated to
establish that the previous care was incorrect or unneces-
Fig 2. Systolic and diastolic blood pressure (95% CI) before and after stenting in patients with and without
post-procedure symptomatic hypotensive events.
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sary. Then a new patient care pathway should be designed
and prospectively investigated. If this pathway is found to
be safe and efficacious, it can then be implemented.
The complication rate with CAS must be at least equal
to or better than that with standard CEA for it to be
accepted as an alternative treatment for carotid artery ste-
nosis. The Carotid and Vertebral Artery Transluminal An-
gioplasty Study (CAVATAS) 1 is thus far the only random-
ized prospective study of reasonable size to compare the
two treatments. Although it showed that the rate of major
outcome events within 30 days of treatment did not differ
significantly between endovascular treatment and surgery
(10.0% vs 9.9%, respectively), the reported complication
rate in the surgical limb of the trial was high when com-
pared with NASCET,7 European Carotid Surgery Trialists
(ECST) study,8 or ASA and Carotid Endarterectomy
(ACE) study,9 (average, 6.3%). However, meaningful com-
parison of the results of CAVATAS with other CEA trials is
limited by differences in case mix, completeness of neuro-
logic evaluation, and nonstandardized end points. Never-
theless, it can be argued that the CAVATAS results are
identical to those recent CEA reports in which outcomes
were assessed by a neurologist.10,11
Complications. The Royal College of Radiologists
and the Society of Cardiovascular and Interventional Radi-
ology recommend 4% as the upper limit for hematomas
requiring surgery, transfusion, or result in delayed dis-
charged, and 0.5% for occlusion at the puncture site after
vascular access for vascular interventions.12,13 In this series,
we had seven (3.4%) major access site complications. It is
interesting that, in 204 procedures performed, manual
compression was the primary method of hemostasis in only
3 patients, all of whom had major access site complications.
Two of these patients had severe atherosclerotic disease of
the common femoral and iliac arteries (one required exter-
nal iliac stenting) and were therefore not candidates to
receive hemostatic devices; in the other patient a 9F access
sheath was used, but no correct sized hemostatic device was
available in the angiography suite at that time. The combi-
nation of large access sheath, atherosclerotic arteries, ag-
gressive anti-platelet therapy, anticoagulation therapy, and
possibly loss of skill in prolonged manual compression (our
unit has been using hemostatic devices in most access sites
6F or larger for 5 years) most likely accounts for the high
complication rate in this group. In comparison, major
access site complications occurred in only 3 of 181 (1.7%)
procedures in which the Angio-Seal hemostatic device was
used, and in 1 of 20 (5%) in which the Closer device was
used. The sample size in the the Closer group, however, is
too small for statistical analysis.
The 30-day all neurologic complication rate of 8.8%
(4.9% transient ischemia, 1.0% nondisabling stroke, and
2.9% major stroke and fatal stroke) in this series is compa-
rable to that in other studies.1-3 Our 30-day any stroke and
death rate was 5.4% (11 of 204 patients), which is almost
identical to that of NASCET (5.8%; 70%-99% stenosis).
Our low neurologic complication rate is likely secondary to
a combination of careful patient selection, optimal antico-
agulation and anti-platelet therapy, and experienced
operators.
Hemodynamic instability, in particular, hypotension, is
a frequent, nonpermanent complication after CAS, with
reported incidence ranging from 22% to 68%.14-16 In this
series, 50.3% of patients had a decrease in systolic pressure
of 40 mm Hg after CAS, but only 7 (3.4%) patients had
symptoms that required treatment. The duration of hypo-
tensive episodes in these 7 patients ranged from 2 to 10
days (mean, 3.7 days). No patients had neurologic events.
In these 7 patients, pharmacologic support (atropine or
phenylephrine) was required in 2; in the remainder, symp-
toms resolved with bed rest and intravenous fluid adminis-
tration. Junior medical staff, before discussion with the
senior staff, instigated most intravenous fluid replacement
therapy. This was probably unnecessary, inasmuch as the
effectiveness of intravenous fluid supplementation in this
circumstance is doubtful. The cause of hypotension after
CAS is likely not hypovolemia but the baroreflex stimula-
tion triggered by the stent. One patient with a history of
unstable angina had ventricular tachycardia after adminis-
tration of atropine during the procedure. Subsequent to
this complication, we have changed our practice and cur-
rently use glycopyrronium bromide, 600 g, rather than
atropine in patients with a history of ischemic heart disease.
Time of complications. Of the 38 complications
documented, 20 (52.6%) occurred within 6 hours of the
procedure, 2 (5.3%) occurred 6 to 12 hours after the
procedure, 3 (7.9%) occurred 12 to 24 hours after the
procedure, and 13 (34.2%) occurred 24 hours to 30 days
after the procedure. Of 18 neurologic complications, 8
(44.4%) occurred within 6 hours post- procedure, 3
(16.7%) occurred between 1 and 3 days post-procedure,
and the remainder (38.9%) occurred after 7 days. The
reason for the large number (55.6%) of late neurologic
events (after day 1) is uncertain. In the ECST trial, it was
suggested that the arch of aorta and heart was the source of
late embolism. The addition of aspirin or warfarin therapy
along with clopidogrel may reduce the incidence of neuro-
logic events in this period, but use of such therapy must be
balanced with increased risk for hemorrhage and other
complications. In short, we are not certain how to deal with
this problem, and no evidence exists in the literature to
guide us.
Is outpatient CAS feasible? Our current policy is to
discharge patients on the day after CAS. If we change our
practice to CAS as an outpatient procedure, patients would
be discharged approximately 6 hours after CAS. In the
present series, five complications occurred 6 to 24 hours
post-CAS, when patients would be at home if the proce-
dure were performed on an outpatient basis. These five
complications included deterioration of renal function in 2
patients, both with a history of renal impairment; and chest
infection, symptomatic hypotension, and death secondary
to a perforated myocardium from the pacing wire in 1
patient each. However, excluding from analysis the data for
the 3 patients who would not be candidates for outpatient
CAS from the outset because of renal impairment and
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temporary pacing, the unexpected complications that oc-
curred in the 6 to 24 hours after CAS were chest infection
and symptomatic hypotension. The patient with chest in-
fection would probably seek medical attention from a fam-
ily practitioner or the local hospital after being discharged.
According to the records, the patient with late-onset hypo-
tension was well and completely independent in the first 24
hours after the procedure. However, immediate post- pro-
cedure blood pressure had decreased significantly in com-
parison with pre-CAS pressure, albeit without symptoms,
from 179/77 mm Hg to 135/62 mm Hg. At the time of
the symptomatic hypotensive event, the pressure had de-
creased further, to 90/50mmHg.With conservative treat-
ment, blood pressure normalized over the next 3 hours.
Subanalysis of hemodynamic changes (Fig 2) showed that
patients with significant reduction in diastolic pressure (15
mm Hg or more) immediately after CAS are at higher risk
for symptomatic hypotension and thus should not be dis-
charged on the day of the procedure.
Use of vascular closure devices enables safe, early mo-
bilization after endovascular therapy.17,18 If a closure de-
vice is not used, eg, in patients with unsuitable vascular
anatomy, same-day discharge is inappropriate, because a
long period of bed rest and immobilization is required after
hemostasis with manual compression. In this series, Angio-
Seal was used successfully in most patients, with a small
incidence of complications, even in the group of patients at
high risk for bleeding because of full anti-platelet treatment
and heparinization. Hence it is prudent that a closure
device be used in patients considered suitable candidates for
same-day discharge.
As with most outpatient procedures, if CAS is consid-
ered, it should be performed in the morning and com-
pleted, at the latest, by mid-afternoon. This enables the
patient to be discharged by early evening (before 7:00 or
8:00 PM), after a 6-hour observation period. Late dis-
charge is unadvisable, because it could be taxing to this
typically older patient population.
What is the benefit of same day discharge? In our
institution, bed occupancy is more than 95% on most days,
and this frequently leads to cancellation of elective proce-
dures to accommodate emergency cases. By performing
CAS on an outpatient basis, demand for inpatient beds is
reduced and cancellation of elective procedures is averted.
In addition, the cost savings may make CAS more finan-
cially attractive.
The main limitation of this study is that it is retrospec-
tive, and thus some minor complications may have been
missed. In addition, data for some patients who required
closer monitoring than others, but did not need active
intervention, were not analyzed. These issues can only be
addressed prospectively.
In conclusion, this review establishes that CAS can be
safely performed on an outpatient basis. However, this does
not mean that all patients can be discharged on the day of
the procedure, becausemany patients are not candidates for
early discharge (Table III). For example, patients with
major comorbid conditions, the elderly, those requiring
anticoagulation therapy post-procedure, patients with im-
paired renal function, and those with unsatisfactory home
circumstances or who live a long distance from the hospital
are not suitable candidates for inpatient CAS.Most of these
factors are entirely predictable before the procedure. How-
ever, those patients with significant reduction in blood
pressure immediately after CAS are best observed for a
longer period, because of the possible development of
hypotension. In patients who are mobile, independent,
have a satisfactory vascular access site, and are free of
complaints or symptoms within 6 hours after the proce-
dure, same-day discharge should be feasible and safe. Since
this study, we have changed our practice and will perform
CAS as an outpatient procedure in suitable patients.
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